Dermatofibroma cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
Line 2: | Line 2: | ||
{{Dermatofibroma}} | {{Dermatofibroma}} | ||
{{CMG}}, {{AE}}{{Homa}} | {{CMG}}, {{AE}}{{Homa}} | ||
==Overview== | |||
==Cost-effectiveness of Therapy== | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] |
Revision as of 21:32, 10 June 2019
Dermatofibroma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Dermatofibroma cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Dermatofibroma cost-effectiveness of therapy |
Risk calculators and risk factors for Dermatofibroma cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]